SEC Targets Glaxo Unit Over Underpriced Stock Buybacks
The U.S. Securities and Exchange Commission on Monday sued Stiefel Laboratories Inc. and its former CEO, alleging they defrauded investors and employees by repurchasing stock at dramatically undervalued prices before a...To view the full article, register now.
Already a subscriber? Click here to view full article